UNASSIGNED: @entity66 ( @entity66 ), due to pro-oxidant species [reactive @entity26 species (ROS)] excess not counterbalanced by endogenous antioxidant molecules [e.g., @entity2041 ( @entity6172 )], is involved in the pathogenesis of @entity1 @entity5 , but few data are available on essential @entity1148 (ET). This study aims to investigate @entity66 in ET off-therapy @entity1 . Thirty ET treatment-na  ve @entity1 were compared with 26 age-matched and gender-matched controls. Serum ROS, urinary @entity7599 , full blood @entity6172 levels, and reduced/oxidized @entity6172 ratio ( @entity6172 / @entity9492 ) were measured. Data were adjusted for gender, age, @entity4016 mutational status, smoking, @entity2299 , or @entity1007 requiring drug therapy, antiplatelet therapy, treatment with @entity117 , high-sensitive @entity1851 levels, and absolute monocyte count. ROS and @entity6172 levels were increased in both @entity1 and controls. @entity1 showed increased @entity9492 (p   =   0.05), reduced @entity6172 / @entity9492 ratio (p   =   0.08), and similar @entity7599 levels when compared with controls. No differences in @entity66 parameters were found between @entity4016 -positive and @entity4016 -negative @entity1 . Confounding factors did not modify the results. Our study suggests an @entity66 in a cohort of treatment-na  ve ET @entity1 , not associated with @entity4016 mutational status or with chronic @entity32 situation. @entity6172 / @entity9492 ratio, altered in ET @entity1 because of increased @entity9492 levels, showed the presence of higher @entity6172 levels in ET than controls as a possible compensatory mechanism of an excess of pro-oxidant production. Copyright    2015 John Wiley _ Sons, Ltd.

Oxidative status in treatment-na  ve essential XXXX : a pilot study in a single center.

@entity1 :: ('9606', 'Species') :: ['human', 'patients', 'Patients'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity1148 :: ('MESH:D013922', 'Disease') :: ['thrombocythemia'] @entity7599 :: ('MESH:C040791', 'Chemical') :: ['8-hydroxydeoxyguanosine'] @entity66 :: ('MESH:D004194', 'Disease') :: ['Oxidative stress', 'OS', 'OS condition'] @entity9492 :: ('MESH:D019803', 'Chemical') :: ['GSSG'] @entity2299 :: ('MESH:D050171', 'Disease') :: ['dyslipidemia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers'] @entity1007 :: ('MESH:D006937', 'Disease') :: ['hypercholesterolemia'] @entity26 :: ('MESH:D010100', 'Chemical') :: ['oxygen'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['acetylsalicylic acid'] @entity2041 :: ('MESH:D005978', 'Chemical') :: ['reduced glutathione'] @entity4016 :: ('3717', 'Gene') :: ['JAK2'] @entity6172 :: ('D005978', 'Chemical') :: ['GSH'] @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein']
@entity1148 :: (MESH:D013922,Disease) :: ['thrombocythemia']
